Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Status
- RECRUITING
- Phase
- PHASE3
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Status
- RECRUITING
- Phase
- PHASE1
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
- Status
- RECRUITING
- Phase
- PHASE2